NCT06989723 - Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Type 2 DiabetesFatty Liver

Interventions

DRUG

Pioglitazone 15 MG [Actos]

Participants will receive pioglitazone 15 mg, administered orally once daily. The tablet may be taken with or without food.

DRUG

Empagliflozin 10 MG [Jardiance]

Participants will receive empagliflozin 10 mg, administered orally once daily. The tablet may be taken with or without food.

DRUG

Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]

Participants will receive one tablet of pioglitazone 15 mg and one tablet of empagliflozin 10 mg, administered orally once daily. Both tablets may be taken with or without food.

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si